OPTUS Pharmaceutical Co (131030) Fair Value & Analysis
Healthcare · KR · Market cap 85.7B KRW
Fair value as of: Jul 22, 2026
From 16 valuation models · updated 19 days ago
Share price +1.2% over the past month.
A solid business, screening 101% undervalued on our models.
What matters now
- The price is below even our cautious bear case (9,120 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 4,585 KRW – 19,260 KRW · fair‑value band 9,120 KRW – 15,200 KRW · the 6,050 KRW price screens below the 12,160 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
OPTUS Pharmaceutical Co (131030) currently trades at 6,050 KRW, while our model-based Fair Value estimate is 12,160 KRW, implying the stock looks roughly 101.0% undervalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, OPTUS Pharmaceutical Co generated revenue of 91.6B KRW at a net margin of 13.9%. Revenue grew 23.8% year over year. It earns a return on equity of 7.9%. Fundamentals as of Jul 22, 2026
Our scenario range runs from 9,120 KRW (bear case) to 15,200 KRW (bull case); at 6,050 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 71% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 101%, 131030 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (14,464 KRW) versus Dividend Discount (1,543 KRW). Highest evidence: Residual Income (76).
Notify me when 131030 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products.
Full company description
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
OPTUS Pharmaceutical Co reported revenue of 87.2B KRW in FY2025 versus 57.3B KRW in FY2021, a compound +11.0%/yr. Reported net income was 11.4B KRW in FY2025, compounding +3.5%/yr from FY2021.
Watch 131030: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare OPTUS Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is OPTUS Pharmaceutical Co (131030) overvalued or undervalued?
What is the fair value of 131030?
What is the quality score of 131030?
What is the revenue of OPTUS Pharmaceutical Co (131030)?
What is the net profit margin of 131030?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track OPTUS Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.